A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

This study tests a new investigational drug delivered directly into the brain via a small pump (similar to a pacemaker for Parkinson's) called continuous subcutaneous infusion, for people with moderate-to-advanced Parkinson's disease whose symptoms are no longer well-controlled by oral medications. **You may be eligible if...** - You are 40–72 years old with a confirmed Parkinson's disease diagnosis for at least 4 years - Your symptoms fluctuate between 'on' (controlled) and 'off' (uncontrolled) periods despite optimized oral medications - Your Parkinson's is in stage 3–4 (moderate to severe) when medications are 'off' - You have had a brain scan (18F-DOPA PET) consistent with Parkinson's disease - Your levodopa medication still provides at least 30% improvement in symptoms **You may NOT be eligible if...** - You have an atypical Parkinson's variant (such as progressive supranuclear palsy or multiple system atrophy) - You have had deep brain stimulation or another implanted brain device - You have significant dementia or psychiatric conditions Talk to your doctor to see if this trial is right for you.